Randomized, double-blind, placebo-controlled study to evaluate the effect of treatment with an SPMs-enriched oil on chronic pain and inflammation, functionality, and quality of life in patients with symptomatic knee osteoarthritis: GAUDI study

Table 3 Quality of life in OA patients (N = 51)

Parameter	Values		P-value
Parameter	SPMs (N = 23)	Placebo (N = 28)	P-value
EQ VAS
Mean change from baseline to week 12, % (SD)	51.8 (216.71)	48.6 (204.17) ⁽¹⁾	0.404 ⁽²⁾
Mobility dimension
Improvement, n (%)	10 (43.48)	7 (25.00)	0.164 ⁽³⁾
Self-care dimension
Improvement, n (%)	7 (30.43)	5 (17.86)	0.292 ⁽³⁾
Usual activities dimension
Improvement, n (%)	12 (52.17)	4 (14.29)	0.004 ⁽³⁾
Pain/discomfort dimension
Improvement, n (%)	14 (60.87)	13 (46.43)	0.304 ⁽³⁾
Anxiety/depression dimension
Improvement, n (%)	6 (26.09)	4 (14.29)	0.162 ⁽⁴⁾

Percentage change in each patient has been used to calculate the mean score change. ⁽⁴⁾ SPM: N = 23, Placebo: N = 27); ⁽²⁾ Mann–Whitney U test; ⁽³⁾ Chi-Square test; ⁽⁴⁾ Fisher’s test; (4) missing data: Placebo, N = 1
EQ VAS: EuroQol Visual Analogue Scale; SPMs: specialized pro-resolving lipid mediators

ISSN: 1479-5876